OOIR: Observatory of International Research

Papers

(The TQCC of ESMO Open is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆	244
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers	147
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN	136
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)	125
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update	103
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies	100
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials	97
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?	91
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment	89
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations	87
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts	87
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of rando	82
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment	82
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines	81
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era	80
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses	72
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies	72
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study	69
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis	67
Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis	66
How I treat biliary tract cancer	63
Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up	62
Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application	62
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort	61
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer	60

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer	57
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer	56
Targeting immunoliposomes to EGFR-positive glioblastoma	55
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer	54
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France	53
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer	52
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration	48
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer	48
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	48
Anti-TIGIT therapies for solid tumors: a systematic review	47
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical	46
How to use liquid biopsies to treat patients with cancer	46
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge	45
Consensus for HER2 alterations testing in non-small-cell lung cancer	44
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring	43
Strategies to tackle RAS-mutated metastatic colorectal cancer	43
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy	42
How we treat primary central nervous system lymphoma	41
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials	40
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study	40
Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study	40
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review	40
Recurrent or primary metastatic cervical cancer: current and future treatments	40
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival	40
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment	39
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	39
Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score	37
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort	37
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies	37
Impact of the COVID-19 pandemic on the care of cancer patients in Spain	37
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus	37
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients	37
How we treat endocrine complications of immune checkpoint inhibitors	36
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts	36
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape	36
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy	36
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study	35
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer	35
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review	35
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials	35
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program	35
Supportive care in patients with cancer during the COVID-19 pandemic	35
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study	35
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022	34
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario	34
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆	34
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up	34
Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy	33
Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature	33
Immune checkpoint inhibitor administration during pregnancy: a case series	33

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies	33
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck	33
How we treat patients with metastatic HER2-positive breast cancer	32
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer	31
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline	31
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer	30
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer	30
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncolog	29
Sex and gender perspectives in colorectal cancer	29
Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials	29
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study	29
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)	29
The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series	28
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia	28
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial	28
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 3	28
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study	27
Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies	27
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States	27
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database	27
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms	27
The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective	27
How we treat HER2-positive brain metastases	27
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903	27
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)	26
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	26
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib	26
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer	26
Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up	26
The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis	26
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review	26
Small-cell lung cancer in never-smokers	25
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards	25
Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer	25
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study	25
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis	25
Targeting HER3 for cancer treatment: a new horizon for an old target	24
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort	24
Distribution of the workforce involved in cancer care: a systematic review of the literature	23
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies	23
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II	23
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations	23
European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN	23
Vaccination against Her-2/neu, with focus on peptide-based vaccines	23
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis	22
Role of molecular genetics in the clinical management of cholangiocarcinoma	22
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy	22
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Canc	22
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	22
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis	22
Breast cancer in very young women—a multicenter 10-year experience	22
Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer	22
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions	22
Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival	22
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer	21
Genomic profiling in non-small-cell lung cancer in young patients. A systematic review	21
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study	21
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours	21
Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey	21
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial	21
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors	21
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	21
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer	20
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients	20
Flexible care in breast cancer	20
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials	20
Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer	20
Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management	20
How we treat esophageal squamous cell carcinoma	20
Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials	20
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer	20
How to read a next-generation sequencing report—what oncologists need to know	20
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey	20
How I treat stage II colon cancer patients	19
Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy	19
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery	19
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma	19
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer	19
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)	19
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)	19

The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression	19
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients	19
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational coho	19
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center	19
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors	18
Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies	18
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patient	18
Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer	18
Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma	18
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study	18
Refining patient selection for breast cancer immunotherapy: beyond PD-L1	18
Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma	17
Targeting KRASG12C in colorectal cancer: the beginning of a new era	17
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study	17
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)	17
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101	17
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery	17
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma	17
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience	17
Emerging targets for anticancer vaccination: IDH	17
Cancer burden in adolescents and young adults in Europe	17
Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit	17
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study	17
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial	17
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	17
Emerging targets for anticancer vaccination: PD-1	17
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?	16
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-	16
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network	16
How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors	16
Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis	16
Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated wi	16
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalut	16
Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)	16
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study	16
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs	16
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy	16
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆	16
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations	16
How I perform fertility preservation in breast cancer patients	16
Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure	16
The DNA damage response network in the treatment of head and neck squamous cell carcinoma	16
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients	16
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey	16
Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and scre	15
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	15
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers	15
Cancer diagnosis in Catalonia (Spain) after two years of COVID-19 pandemic: an incomplete recovery	15
Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’	15
High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different soli	15
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network	15
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	15
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer	15
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer	15
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer	15
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer	15
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma	15
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials	15
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program	15
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis	15
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy	15
How I treat diffuse large B-cell lymphoma	15
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer	14
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern	14
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate	14
Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life	14
Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis	14
Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome	14
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study	14
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study	14
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma	14
The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study	14
Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials	14
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?	14
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics	13
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	13
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer	13
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases	13
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an upda	13
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer	13
Symptom burden, psychological distress, and symptom management status in hospitalized patients with advanced cancer: a multicenter study in China	13
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients	13
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment	13
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)	13
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial	13
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network	13
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study	13
Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels	13
Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline	13
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group	12
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study	12
The current role of precision surgery in oligometastatic prostate cancer	12
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer	12
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy	12
Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers	12